{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:27:17Z","timestamp":1790958437502,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2025GH-YBXM-069"],"award-info":[{"award-number":["2025GH-YBXM-069"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xphs.2025.104026","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T23:30:44Z","timestamp":1760398244000},"page":"104026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes"],"prefix":"10.1016","volume":"115","author":[{"given":"Xiaoxuan","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-5333","authenticated-orcid":false,"given":"Simin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-7858","authenticated-orcid":false,"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7433-3711","authenticated-orcid":false,"given":"Sifei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0369-2907","authenticated-orcid":false,"given":"Luojuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2025.104026_bib0001","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.xphs.2025.104026_bib0002","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.xphs.2025.104026_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2025.104026_bib0004","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.xphs.2025.104026_bib0005","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.xphs.2025.104026_bib0006","doi-asserted-by":"crossref","first-page":"e1514","DOI":"10.1002\/onco.13817","article-title":"First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.xphs.2025.104026_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1358\/dot.2023.59.3.3507759","article-title":"Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer","volume":"59","author":"Sakamoto","year":"2023","journal-title":"Drugs Today"},{"issue":"1","key":"10.1016\/j.xphs.2025.104026_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.xphs.2025.104026_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.xphs.2025.104026_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O'Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.xphs.2025.104026_bib0011","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Fut Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104026_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting","volume":"7","author":"McCloskey","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.xphs.2025.104026_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114156","article-title":"An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologics","volume":"386","author":"Bruin","year":"2025","journal-title":"J Controll Rel"},{"issue":"10","key":"10.1016\/j.xphs.2025.104026_bib0014","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14712598.2022.2125799","article-title":"Envafolimab \u2013 first PD-1\/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/j.xphs.2025.104026_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.trecan.2024.03.006","article-title":"The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations","volume":"10","author":"Hadfield","year":"2024","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.xphs.2025.104026_bib0016","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.xphs.2025.104026_bib0017","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104026_bib0018","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.xphs.2025.104026_bib0019","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.xphs.2025.104026_bib0020","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2019.0836","article-title":"Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial","volume":"5","author":"Johnson","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.104026_bib0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-409X(01)00153-3","article-title":"Lymphatic transport of proteins after S.C. injection: implications of animal model selection","volume":"50","author":"Porter","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.xphs.2025.104026_bib0022","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ejpb.2007.04.002","article-title":"The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model","volume":"67","author":"Kagan","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0023","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp400464s","article-title":"The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats","volume":"11","author":"Dahlberg","year":"2014","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2025.104026_bib0024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11095-020-02860-6","article-title":"Lymphatic distribution of etanercept following intravenous and subcutaneous delivery to rats","volume":"37","author":"Gao","year":"2020","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2025.104026_bib0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/dmd.111.043604","article-title":"Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs","volume":"40","author":"Wang","year":"2012","journal-title":"Drug Metabol Disposit"},{"issue":"3","key":"10.1016\/j.xphs.2025.104026_bib0026","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"Aaps J"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0027","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1520-6017(200002)89:2<168::AID-JPS4>3.0.CO;2-Q","article-title":"Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection","volume":"89","author":"Charman","year":"2000","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2025.104026_bib0028","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.xphs.2025.104026_bib0029","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1084\/jem.20062596","article-title":"Functionally specialized junctions between endothelial cells of lymphatic vessels","volume":"204","author":"Baluk","year":"2007","journal-title":"J Exp Med"},{"issue":"4622","key":"10.1016\/j.xphs.2025.104026_bib0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.6623082","article-title":"Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor","volume":"222","author":"Weinstein","year":"1983","journal-title":"Science"},{"issue":"4579","key":"10.1016\/j.xphs.2025.104026_bib0031","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1126\/science.7146917","article-title":"Monoclonal anitbodies in the lymphatics: toward the diagnosis and therapy of tumor metastases","volume":"218","author":"Weinstein","year":"1982","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.xphs.2025.104026_bib0032","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.xphs.2025.104026_bib0033","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10585-021-10120-z","article-title":"Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels","volume":"39","author":"Leong","year":"2021","journal-title":"Clin Exp Metast"},{"key":"10.1016\/j.xphs.2025.104026_bib0034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.03.018","article-title":"Multiple roles of lymphatic vessels in tumor progression","volume":"53","author":"Ma","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"23","key":"10.1016\/j.xphs.2025.104026_bib0035","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"issue":"563","key":"10.1016\/j.xphs.2025.104026_bib0036","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay3575","article-title":"Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy","volume":"12","author":"Francis","year":"2020","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.xphs.2025.104026_bib0037","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/ar.21446","article-title":"Demonstrating the lymphatic system in rats with microinjection","volume":"294","author":"Suami","year":"2011","journal-title":"Anatom Rec"},{"issue":"Pt 3","key":"10.1016\/j.xphs.2025.104026_bib0038","first-page":"369","article-title":"Patterns of lymphatic drainage in the adult laboratory rat","volume":"109","author":"Tilney","year":"1971","journal-title":"J Anat"},{"key":"10.1016\/j.xphs.2025.104026_bib0039","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2019.10.040","article-title":"Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats","volume":"315","author":"Styles","year":"2019","journal-title":"J Controll Rel"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.vascn.2003.11.004","article-title":"A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat","volume":"49","author":"Boyd","year":"2004","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.xphs.2025.104026_bib0041","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.12.031","article-title":"Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery","volume":"272","author":"Yadav","year":"2018","journal-title":"J Controll Rel"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0042","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.xphs.2025.104026_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer","volume":"385","author":"Palaskas","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0044","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"issue":"103","key":"10.1016\/j.xphs.2025.104026_bib0046","doi-asserted-by":"crossref","first-page":"eads6295","DOI":"10.1126\/sciimmunol.ads6295","article-title":"Functional differences between rodent and human PD-1 linked to evolutionary divergence","volume":"10","author":"Masubuchi","year":"2025","journal-title":"Sci Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2025.104026_bib0047","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1535-7163.MCT-19-0774","article-title":"Biophysical and immunological characterization and in vivo pharmacokinetics and toxicology in nonhuman primates of the anti-PD-1 antibody pembrolizumab","volume":"19","author":"Hutchins","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.xphs.2025.104026_bib0048","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.xphs.2025.104026_bib0049","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discov"},{"issue":"16_Supplement","key":"10.1016\/j.xphs.2025.104026_bib0050","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1538-7445.AM2020-3260","article-title":"Abstract 3260: the preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation","volume":"80","author":"Zhang","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.xphs.2025.104026_bib0051","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpb.2022.02.014","article-title":"Intra-articular injection of biologic anti-rheumatic drugs enhances local exposure to the joint-draining lymphatics","volume":"173","author":"Lam","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2025.104026_bib0052","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jconrel.2024.03.032","article-title":"Impact of conjugation to different lipids on the lymphatic uptake and biodistribution of brush PEG polymers","volume":"369","author":"Abdallah","year":"2024","journal-title":"J Controll Rel"},{"issue":"10","key":"10.1016\/j.xphs.2025.104026_bib0053","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1021\/acs.bioconjchem.6b00487","article-title":"Albumin-binding Evans Blue derivatives for diagnostic imaging and production of long-acting therapeutics","volume":"27","author":"Jacobson","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.xphs.2025.104026_bib0054","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2020.07.046","article-title":"Lymphatic targeting by albumin-hitchhiking: applications and optimisation","volume":"327","author":"Abdallah","year":"2020","journal-title":"J Controll Rel"},{"issue":"2","key":"10.1016\/j.xphs.2025.104026_bib0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11095-011-0578-3","article-title":"Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats","volume":"29","author":"Kagan","year":"2011","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:06:01Z","timestamp":1777421161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925004800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022354925004800"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104026","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104026"}}